Newsroom | 30713 results

DUBLIN--(BUSINESS WIRE)--The "Fluoroform (CAS 75-46-7) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. This report on Fluoroform provides comprehensive insights, including general information, synonyms, chemical composition, safety, hazards, handling, storage, and toxicological and ecological details, along with transport information. This in-depth study serves as a vital resource for understan...

東京--(BUSINESS WIRE)--(美國商業資訊)-- Rigaku Holdings Corporation旗下子公司Rigaku Corporation（總部：東京昭島市；執行長：Jun Kawakami；以下簡稱「Rigaku」），與SPERA PHARMA, Inc.（總部：大阪市；董事長兼代表董事：Keitaro Iwaki；以下簡稱「SPERA PHARMA」）宣佈達成戰略合作，旨在通過整合雙方尖端技術與深厚專業知識，加速並革新藥物研發進程。 SPERA PHARMA將採用Rigaku提供的電子衍射集成平台XtaLAB Synergy-ED開展合約分析服務，為客戶的藥物研發提供強力支援。 XtaLAB Synergy-ED搭載的3D ED/MicroED1可用於物質結構分析，包括顯微晶體和微量結晶粉末。這項尖端技術具有足夠高的解析度，可以確定原子級結構，從而詳細闡明有機化合物及類似物質的分子結構。 SPERA PHARMA目前是全球醫藥行業唯一一家提供XtaLAB Synergy-ED合約分析服務的企業。Rigaku將為SPERA PHARMA的合約分析業務提供全面...

东京--(BUSINESS WIRE)--(美国商业资讯)-- Rigaku Holdings Corporation旗下子公司Rigaku Corporation（总部：东京昭岛市；首席执行官：Jun Kawakami；以下简称“Rigaku”），与SPERA PHARMA, Inc.（总部：大阪市；董事长兼代表董事：Keitaro Iwaki；以下简称“SPERA PHARMA”）宣布达成战略合作，旨在通过整合双方尖端技术与深厚专业知识，加速并革新药物研发进程。 SPERA PHARMA将采用Rigaku提供的电子衍射集成平台XtaLAB Synergy-ED开展合约分析服务，为客户的药物研发提供强力支持。 XtaLAB Synergy-ED搭载的3D ED/MicroED1可用于物质结构分析，包括显微晶体和微量结晶粉末。这项尖端技术具有足够高的分辨率，可以确定原子级结构，实现有机化合物和类似物质分子结构的精密阐明。 SPERA PHARMA目前是全球医药行业唯一一家提供XtaLAB Synergy-ED合约分析服务的企业。Rigaku将为SPERA PHARMA的合约分析业务提供...

ORLANDO, Fla.--(BUSINESS WIRE)--Beamer Laser Marking Systems (“Beamer” or “the Company”), a trusted U.S.-based provider of industrial fiber and CO2 laser marking equipment for high-precision applications, today announced an exciting new phase for the Company. Following its recent acquisition by Fonon Quantum Technologies, Inc. (FQTI), operations are now fully integrated into a state-of-the-art facility in Orlando, Fla. This transformative move positions Beamer for accelerated growth and continu...

MAYFIELD HEIGHTS, Ohio--(BUSINESS WIRE)--Materion Corporation (NYSE: MTRN) is scheduled to release its first quarter 2025 financial results on May 1, 2025, before the opening of the New York Stock Exchange. The company will hold a conference call with investors at 10:00 AM ET that morning. Jugal Vijayvargiya, President and Chief Executive Officer, and Shelly Chadwick, Vice President, Finance and Chief Financial Officer, will represent Materion Corporation on the call. Conference Call and Slide...

TOKYO--(BUSINESS WIRE)--Rigaku Corporation, azienda del Gruppo di Rigaku Holdings Corporation (sede centrale: Akishima, Tokyo; CEO: Jun Kawakami; di seguito “Rigaku”), e SPERA PHARMA, Inc. (sede centrale: Osaka; Presidente e Direttore rappresentante: Keitaro Iwaki; di seguito “SPERA PHARMA”) hanno avviato una collaborazione strategica mirata ad accelerare e trasformare uno sviluppo farmaceutico utilizzando le tecnologie all'avanguardia e le vaste competenze delle due aziende. SPERA PHARMA utili...

TOKIO--(BUSINESS WIRE)--Rigaku Corporation, empresa del grupo Rigaku Holdings Corporation (sede central: Akishima, Tokio; gerente general: Jun Kawakami; en adelante, ''Rigaku''), y SPERA PHARMA, Inc. (sede central: Osaka; presidente y director representante: Keitaro Iwaki; en adelante, ''SPERA PHARMA'') iniciaron una asociación estratégica destinada a acelerar y transformar el desarrollo farmacéutico, aprovechando las tecnologías de vanguardia y la vasta experiencia de ambas empresas. XtaLAB Sy...

TOKIO--(BUSINESS WIRE)--Die Rigaku Corporation, ein Konzernunternehmen der Rigaku Holdings Corporation (Hauptsitz: Akishima, Tokio; CEO: Jun Kawakami; im Folgenden „Rigaku“) und SPERA PHARMA, Inc. (Hauptsitz: Osaka; President & Representative Director: Keitaro Iwaki; im Folgenden „SPERA PHARMA“) haben eine strategische Partnerschaft geschlossen, um die pharmazeutische Entwicklung durch die Nutzung der hochmodernen Technologien und des umfassenden Fachwissens beider Unternehmen zu beschleuni...

TOKYO--(BUSINESS WIRE)--Rigaku Corporation, een groepsmaatschappij van Rigaku Holdings Corporation (hoofdkantoor: Akishima, Tokyo; CEO: Jun Kawakami; hierna 'Rigaku'), en SPERA PHARMA, Inc. (hoofdkantoor: Osaka; president en vertegenwoordigend directeur: Keitaro Iwaki; hierna 'SPERA PHARMA') zijn een strategische samenwerking aangegaan die gericht is op het versnellen en transformeren van farmaceutische ontwikkeling door de geavanceerde technologieën en uitgebreide expertise van beide bedrijven...

TÓQUIO--(BUSINESS WIRE)--A Rigaku Corporation, uma empresa do Grupo Rigaku Holdings Corporation (sede: Akishima, Tóquio; CEO: Jun Kawakami; denominada aqui “Rigaku”), e a SPERA PHARMA, Inc. (sede: Osaka; presidente e diretor representante: Keitaro Iwaki; denominada aqui “SPERA PHARMA”) iniciaram uma parceria estratégica com o objetivo de acelerar e transformar o desenvolvimento farmacêutico, aproveitando as tecnologias de ponta e a ampla experiência das duas empresas. A SPERA PHARMA usará o Xta...